Overweight and Obesity
Pipeline by Development Stage
Drug Modality Breakdown
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 15.0yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.4yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.6yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
Competitive Landscape
27 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 15,590 patients across 50 trials
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human
A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity
Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
A Mindfulness-Based Intervention to Reduce Stress Through the Cultivation of Loving-Kindness, Compassion, Joy, and Equanimity in Healthcare Professionals
Intervention Trial for Healthcare Workers With Anxiety
Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage
Time and Nutrient-Dependent Effects of Aerobic Exercise on Metabolism in Adults (TANDEM Study)
Train Your Brain - Executive Function
The Prevention And Treatment On Obesity And Weight Management By Oral Supplementation Of Probiotics And Prebiotics
Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)
Early vs. Late Time Restricted Eating vs. Daily Caloric Restriction
Dietitian Online - Internet-based Dietetic Treatment Within Health Care Services
A 12-week Field Trial of the Move Physical Activity Support Program
Interindividual Variation in Response to Green Coffee
The Effect of Colchicine on Food-related Effort-based Decision Making in Brain and Behaviour in Overweight and Obesity
Weight Loss Intervention With Lean Muscle Mass Retention
Impact of Microbiome-changing Interventions on Food Decision-making
Califormula Study: Calibrated Formula Feeding to Optimize Infant Growth
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)
Enhancing BodyWorks: a Canine Health Literacy Module
Insulin and Muscle Fat Metabolism
Pilot Study on Weight Loss in Guinea Bissau
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity
Time-restricted Feeding as a Dietary Strategy Against Metabolic Disturbances in Humans
Effects of Pecan Nut Snacks v Equicaloric Snacks on Appetite, Food Intake, Metabolism, Hormones and Biomarkers
Study of the Effects of Overfeeding on Glucocorticoids in Lean and Obese Subjects
Morning Versus Evening Exercise for Adults With Overweight and Obesity
Project Health: Enhancing Effectiveness of an Obesity Prevention Program
Improving Nutritional Choices in Adolescents
Episodic Future Thinking and Weight-Loss
Circadian Timing, Information Processing and Energy Balance Study
Project Health: Enhancing Effectiveness of a Dissonance-Based Obesity Prevention Program
Devaluing Foods to Change Eating Behavior
Evaluation of the Effect of Epitomee Device on Gastric Emptying Rate in Healthy Subjects
Understanding Mechanisms of Exercise Behavior Change
Feasibility and Preliminary Efficacy of a Reverse Diet as a Novel Weight Loss Maintenance Strategy for Weight-Reduced Adults With Overweight/Obesity
Pilot Study of the HWL Program
Influence of Resistant Starch Intake in Potatoes on Blood Glucose and Satiety Responses in Overweight Females
Effects of Inhibitory Control Training in Eating Behaviors
Understanding Mechanisms of Health Behavior Change
Related Jobs in Metabolic Diseases
Associate Director, SEC Reporting & Technical Accounting
Head of Manufacturing
Clinical Diabetes Specialist - New Haven
Territory Business Leader - Columbia SC
Territory Business Leader - Seattle
Territory Business Leader- Phoenix North
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.